<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312688</article-id>
      <article-id pub-id-type="pmc">4540522</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153545</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cutaneous histoplasmosis as a complication after anti-TNF use - Case
report<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zattar</surname>
            <given-names>Gabrielle Aline</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cardoso</surname>
            <given-names>Fernanda</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakandakari</surname>
            <given-names>Sadamitsu</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soares</surname>
            <given-names>Cleverson Teixeira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Lauro de Souza Lima Institute (ILSL) - Bauru (SP),
Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Gabrielle Aline Zattar, Rodovia Comandante Jo&#xE3;o
Ribeiro de Barros km 225/226, 17034-971 - Bauru - SP, Brazil. E-mail:
<email>gabi.zattar@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>104</fpage>
      <lpage>107</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Anti-TNF agents are effective in the treatment of psoriasis. However, they render
individuals more susceptible to infections. We report an atypical case of
histoplasmosis in an immunosuppressed patient due to anti- TNF therapy. A patient who
used anti-TNF for the treatment of psoriasis had had a lesion on the right eyebrow
since discontinuation of the medication. The diagnostic hypothesis was basal cell
carcinoma, but the histopathological examination was compatible with
histoplasmosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Histoplasmosis</kwd>
        <kwd>Immunosuppression</kwd>
        <kwd>Immunosuppressive agents</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Tumor necrosis factor (TNF)-neutralizing agents are effective in treating various
inflammatory conditions in which this cytokine is considered to play an important role.
In dermatology it is used to treat psoriasis.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> TNF is essential for the formation and maintenance of granulomas,
which are important components of host defense against intracellular
pathogens.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> Anti-TNF agents inhibit the proliferation of T-cells and
alter Th1 immune response, increasing individuals' susceptibility to infections. There
are currently three anti-TNF agents available for use in clinical practice: Infliximab
and adalimumab are monoclonal anti-TNF-&#x3B1; antibodies and etanercept is a bivalent soluble
TNF receptor (fusion protein).</p>
      <p>Histoplasmosis is a systemic infection caused by the dimorphic fungus
<italic>Histoplasma capsulatum</italic>, which transforms into a pathogenic yeast
once inhaled. Its incidence has increased after the introduction of anti-TNF.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup>
We report an atypical case of histoplasmosis in immunosuppressed patients due to use of
anti-TNF.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 46-year-old male patient had had a lesion on the right eyebrow for three months, ever
since adalimumab use had been discontinued. The patient used etanercept for 2 years and
3 months, then adalimumab for 6 months until discontinuation of the treatment. Both
drugs had been prescribed for the treatment of 'difficult-to-control' psoriasis. He had
no mucosal lesions, lymphadenopathy or systemic symptoms. The patient denied
comorbidities as well as contact with birds or bats.</p>
      <p>Clinical examination revealed a single papular, erythematous and infiltrated lesion with
slight scaling on the surface. The diagnostic hypothesis was basal cell carcinoma (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). A biopsy revealed chronic granulomatous dermatitis with areas of caseous
necrosis and giant cell reaction. There were small round fungal structures surrounded by
a clear halo within the macrophages and the necrotic area, which were morphologically
consistent with <italic>Histoplasma capsulatum</italic> (<xref ref-type="fig" rid="f03">Figures 3</xref> to <xref ref-type="fig" rid="f05">5</xref>). The culture for fungi
and mycobacteria gave negative results. Chest radiography showed no changes. Serology
was negative for paracoccidioidomycosis and serology for histoplasmosis was not
performed due to unavailability.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Papular erythematous, infiltrated lesion with slight superficial scaling on the
right eyebrow</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0104-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>A:</bold> detail of the lesion simulating basal cell carcinoma.
<bold>B:</bold> Dermoscopy of the lesion shows arborizing telangiectasias on
the periphery of the lesion and superficial scaling</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0104-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Skin with intense pseudocarcinomatous epithelial hyperplasia associated with
granulomatous inflammation in the dermis. (HE - 20x)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0104-g03"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p><bold>A:</bold> Small round fungi morphologically compatible with Histoplasma
within granulomas (methenamine silver). <bold>B:</bold> Small round fungi within
macrophages (PAS with diastase)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0104-g05"/>
      </fig>
      <p>Due to these findings, the patient was treated with itraconazole 400 mg daily for 6
months, with regression of the lesion.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Most infections by <italic>Histoplasma capsulatum</italic> are asymptomatic.<sup><xref rid="r05" ref-type="bibr">5</xref></sup> Symptomatic forms include primary and
chronic pulmonary histoplasmosis, and localized or disseminated
histoplasmosis.<sup><xref rid="r06" ref-type="bibr">6</xref></sup> Fungus spores
are found in caves, attics, abandoned houses, henneries and the soil. Animal reservoirs
are bats, chickens and gregarious birds.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> The infection is often
produced from inhaling spores of the fungus and the host's immune response determines
the extent of the disease. A key factor in the development of symptoms is the size of
the inoculum. Other factors involved are the virulence of the pathogen, and the host's
age and primary underlying diseases.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>Histoplasmosis skin lesions are polymorphic. Histopathologically, granulomas are
uncommon, while an infiltrate composed of macrophages infected by the microorganism is
most commonly seen. <sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> The diagnosis is made clinically, epidemiologically and
through laboratory testing (culture, histopathology and serology).<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>In our case, despite the unusual epidemiology - the patient denied any contact with
birds and bats - the histopathological examination was essential for the diagnosis,
because it showed fungal structures compatible with <italic>Histoplasma
capsulatum</italic>. In addition, the culture of the lesion fragment for fungus was
only performed after removing a significant portion of the fragment for
histopathological examination. The shortage of material may have contributed to the
negative results.</p>
      <p>The main differential diagnoses for these histopathological findings include
paracoccidioidomycosis and leishmaniasis. However, <italic>Paracoccidioides
brasiliensis</italic> is a larger fungus that has multiple budding, assuming the
aspect of a "rudder wheel"; <italic>Leishmania sp</italic>. is not stained by silver;
and both do not show the typical clear halo described, which essentially excludes these
diagnoses. <sup><xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>Immunomodulatory therapy anti-TNF-&#x3B1; agents poses a risk of developing
histoplasmosis.<sup><xref rid="r09" ref-type="bibr">9</xref></sup> In
immunocompromised patients, the infection is often widespread, unlike the case reported
here. The occurrence of histoplasmosis in these patients is probably the result of
reactivation of latent infection or new exposure (or re-exposure) of the host to the
organism.<sup><xref rid="r09" ref-type="bibr">9</xref></sup></p>
      <p>Most cases found in the literature on the association of histoplasmosis with the use of
anti-TNF were patients coming from endemic regions, who had been treated with multiple
immunomodulatory agents, just like our case.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r09" ref-type="bibr">9</xref>-<xref rid="r11" ref-type="bibr">11</xref></sup> Infliximab was the most
common anti-TNF agent used.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r09" ref-type="bibr">9</xref>-<xref rid="r11" ref-type="bibr">11</xref></sup></p>
      <p>We emphasize the importance of considering histoplasmosis as a differential diagnosis of
cutaneous lesions in immunosuppressed patients. Moreover, patients using these
medications should be counseled to avoid activities that increase the risk of exposure
to the pathogen, such as exploring caves and cleaning bird droppings.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Zattar GA, Cardoso F, Nakandakari S, Soares
CT. Cutaneous histoplasmosis as a complication after anti-TNF use: a case report. An
Bras Dermatol. 2015;90 (3 Suppl 1):S104-7</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Lauro de Souza Lima Institute (ILSL) - Bauru (SP), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Slifman</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Gershon</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Schwieterman</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>JN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Life-threatening histoplasmosis complicating immunotherapy with tumor
necrosis factor a antagonists infliximab and etanercept</article-title>
          <source>Arthritis Rheum</source>
          <year>2002</year>
          <volume>46</volume>
          <fpage>2565</fpage>
          <lpage>2570</lpage>
          <pub-id pub-id-type="pmid">12384912</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakleh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tleyjeh</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Matteson</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Osmon</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Berbari</surname>
              <given-names>EF</given-names>
            </name>
          </person-group>
          <article-title>Infectious complications of tumor necrosis factor-alpha
antagonists</article-title>
          <source>Int J Dermatol</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>443</fpage>
          <lpage>448</lpage>
          <pub-id pub-id-type="pmid">15941429</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallis</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Broder</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Beenhouwer</surname>
              <given-names>DO</given-names>
            </name>
          </person-group>
          <article-title>Granulomatous infectious diseases associated with tumor necrosis
factor antagonists</article-title>
          <source>Clin Infect Dis</source>
          <year>2004</year>
          <volume>38</volume>
          <fpage>1261</fpage>
          <lpage>1265</lpage>
          <pub-id pub-id-type="pmid">15127338</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deepe</surname>
              <given-names>GS</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>T cells require tumor necrosis factor-a to provide protective immunity
in mice infected with Histoplasma capsulatum</article-title>
          <source>J Infect Dis</source>
          <year>2006</year>
          <volume>193</volume>
          <fpage>322</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">16362898</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Brasil</collab>
            <collab>Minist&#xE9;rio da Sa&#xFA;de</collab>
            <collab>Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de</collab>
            <collab>Departamento de Vigil&#xE2;ncia Epidemiol&#xF3;gica</collab>
          </person-group>
          <source>Minist&#xE9;rio da Sa&#xFA;de.Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de. Departamento de
Vigil&#xE2;ncia Epidemiol&#xF3;gica. Doen&#xE7;as infecciosas e parasit&#xE1;rias</source>
          <edition>8. ed. rev</edition>
          <publisher-loc>Bras&#xED;lia</publisher-loc>
          <publisher-name>Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
          <year>2010</year>
          <size units="pages">448p</size>
          <comment>il. - (Serie B. Textos B&#xE1;sicos de Sa&#xFA;de)</comment>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Azulay</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Azulay</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Azulay-Abulafia</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <source>Dermatologia</source>
          <edition>6. ed</edition>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Guanabara Koogan</publisher-name>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rodas</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Skin lesions in histoplasmosis</article-title>
          <source>Clin Dermatol</source>
          <year>2012</year>
          <volume>30</volume>
          <fpage>592</fpage>
          <lpage>598</lpage>
          <pub-id pub-id-type="pmid">23068146</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vidyanath</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shameena</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sudha</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Disseminated histoplasmosis with oral and cutaneous
manifestations</article-title>
          <source>J Oral Maxillofac Pathol</source>
          <year>2013</year>
          <volume>17</volume>
          <fpage>139</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">23798850</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Bongartz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Crowson</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Orenstein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Matteson</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Histoplasmosis infection in patients with rheumatoid arthritis,
1998-2009</article-title>
          <source>BMC Infect Dis</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>145</fpage>
          <lpage>145</lpage>
          <pub-id pub-id-type="pmid">21605439</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsiodras</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Samonis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Boumpas</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Kontoyiannis</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Fungal infections complicating tumor necrosis factor alpha blockade
therapy</article-title>
          <source>Mayo Clin Proc</source>
          <year>2008</year>
          <volume>83</volume>
          <fpage>181</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">18241628</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wood</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Hage</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Knox</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Kleiman</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Sannuti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>RB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Histoplasmosis after treatment with anti-tumor necrosis factor-alpha
therapy</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>167</volume>
          <fpage>1279</fpage>
          <lpage>1282</lpage>
          <pub-id pub-id-type="pmid">12615627</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f04" orientation="portrait" position="float">
      <label>FIGURE 4</label>
      <caption>
        <p><bold>A:</bold> Chronic granulomatous inflammation with epithelioid histiocytes,
multinucleated giant cells and areas of necrosis (HE - 10x). <bold>B:</bold> Detailed
view - visualization of small round fungal structures surrounded by a clear halo
within giant multinucleated cells and the necrotic area (HE - 40x)</p>
      </caption>
      <graphic xlink:href="abd-90-03-s1-0104-g04"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
